[Modern differential-therapeutic aspects of the drug therapy of chronic gout].
The present paper adopts a definite attitude to the differentiated therapy of the disturbances of the uric acid metabolism. This demands an exacter subdivision of the kind of the metabolic disturbance (types Ia, Ib, IIa, IIb, and III). On the basis of this classification in types an individually adapted therapy is possible. It might form the prerequisite of a still more effective meeting of the nephrogenic complications of the gout and of the reduction of the side effects of the necessary permanent therapy.
D000493:Allopurinol / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000150:complications; D002951:Citrates / Q000627:therapeutic use; D006073:Gout / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000150:complications; D007674:Kidney Diseases / Q000209:etiology; D009765:Obesity / Q000209:etiology; D010653:Phenylbutazone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D014527:Uric Acid / Q000378:metabolism; D014545:Urinary Calculi / Q000209:etiology
D002951:Citrates; D014527:Uric Acid; D000493:Allopurinol; D010653:Phenylbutazone
Moderne differentialtherapeutische Aspekte der medikamentösen Behandlung der chronischen Gicht.